Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Fresenius Kabi USA, LLC v. Watson Laboratories Inc. et al
Case Number:
1:13-cv-01015
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 25, 2014
Fresenius Loses Diprivan IP Suit Against Actavis, Dr. Reddy's
Fresenius Kabi USA LLC has lost its bid to show that Actavis Inc. and India-based Dr. Reddy's Laboratories Ltd. infringed four of Fresenius' patents by attempting to market a generic form of the sedative and anesthetic Diprivan, according to a trial opinion filed Monday in Delaware federal court.
-
June 07, 2013
Fresenius Targets Actavis With IP Suit Over Diprivan
Fresenius Kabi USA LLC launched a suit in Delaware federal court Thursday alleging Actavis Inc. and its subsidiary Watson Laboratories infringed four patents by attempting to market a generic form of the sedative and anesthetic Diprivan.